Study details
Enrolling now
Dose Ranging Trial of ORKA-001 for Psoriasis
Oruka Therapeutics, Inc.
NCT IDNCT07290569ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
160
Study length
about 3.1 years
Ages
18+
Locations
20 sites in AR, AZ, CA +11
What this study is about
This trial is testing different doses of ORKA-001 to see if it helps with moderate-to-severe plaque psoriasis. Participants will be randomly assigned to receive either ORKA-001 or a placebo, and it will last about 1 year.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Placebo
- 2.Take ORKA-001
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Secondary: Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Body systems
Dermatology